EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Sodium Glucose‐Like Co‐Transporter 2 Inhibitor ( SGLT2i ) Use in Adults With Cystic Fibrosis

Ellie Johnson iD, Angela Matson iD, Robyn Cobb, Shanal Kumar iD

Respirology Case Reports · 2026-03 · 14 (3)

DOI: 10.1002/rcr2.70533 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Respirology Case Reports, online erschienen am 12.03.2026. Verfasst von Ellie Johnson und 3 weiteren Autor:innen. Beteiligte Einrichtung: The Prince Charles Hospital, Adult Cystic Fibrosis Centre Brisbane Australia. Die Arbeit nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sodium‐glucose cotransporter 2 inhibitors (SGLT2i) also called flozins or gliflozins have been demonstrated to have multi‐system benefits across the endocrine, metabolic, renal and cardiovascular systems. As a result, indications for use of SGLT2i have grown, however, there is limited evidence describing their use in people with CF (pwCF). We describe safe, tolerable and effective use of SGLT2i in three adults with CF. Indications for SGLT2i in our three cases varied. Our first case required it for glycaemic management due to predominantly type 2 diabetes phenotype. The next case had heavy proteinuria due to CF diabetes‐related nephropathy. And the last case had non‐diabetes related nephropathy. All cases tolerated SGLT2i without any side effects. Our findings add to the limited literature on SGLT2i use in pwCF, which will become increasingly relevant given an ageing CF population in the post‐modulator era.

Schlagwörter

Stichwörter der Autor:innen

case seriescystic fibrosisdiabetesrenal diseasesodium glucose co‐transporter 2 inhibitors

Autor:innen und Institutionen

  • The Prince Charles Hospital, Adult Cystic Fibrosis Centre Brisbane Australia.
  • Dept Nutrition & Dietetics Allied Health, the Prince Charles Hospital, Adult Cystic Fibrosis Centre Brisbane Australia.
  • Dept Physiotherapy Allied Health the Prince Charles Hospital Chermside Queensland Australia.
  • Senior Lecturer, University of Queensland St Lucia Queensland Australia.

ORCID-Profile: Ellie Johnson, Angela Matson, Shanal Kumar

Zitieren

APA

Johnson, E., Matson, A., Cobb, R., & Kumar, S. (2026). Sodium Glucose‐Like Co‐Transporter 2 Inhibitor ( SGLT2i ) Use in Adults With Cystic Fibrosis. Respirology Case Reports, 14(3). https://doi.org/10.1002/rcr2.70533

Vancouver

Johnson E, Matson A, Cobb R, Kumar S. Sodium Glucose‐Like Co‐Transporter 2 Inhibitor ( SGLT2i ) Use in Adults With Cystic Fibrosis. Respirology Case Reports. 2026;14(3). doi:10.1002/rcr2.70533

BibTeX
@article{Johnson2026,
  author = {Johnson, Ellie and Matson, Angela and Cobb, Robyn and Kumar, Shanal},
  title = {Sodium Glucose‐Like Co‐Transporter 2 Inhibitor ( SGLT2i ) Use in Adults With Cystic Fibrosis},
  journal = {Respirology Case Reports},
  year = {2026},
  volume = {14},
  number = {3},
  doi = {10.1002/rcr2.70533}
}
Kostenlos starten →